DrugPatentWatch Database Preview
Details for Patent: 8,207,297
Try a free trial
See Plans and Pricing
Which drugs does patent 8,207,297 protect, and when does it expire?
Patent 8,207,297 protects KYPROLIS and is included in one NDA.
This patent has eighty-four patent family members in twenty-six countries.
Summary for Patent: 8,207,297
| Title: | Compounds for enzyme inhibition |
| Abstract: | Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. |
| Inventor(s): | Smyth; Mark S. (Foster City, CA), Laidig; Guy J. (Menlo Park, CA) |
| Assignee: | Onyx Therapeutics, Inc. (South San Francisco, CA) |
| Application Number: | 13/334,469 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,207,297 |
|
Patent Claim Types: see list of patent claims | Use; Process; Composition; Formulation; Dosage form; Compound; |
Drugs Protected by US Patent 8,207,297
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | |||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | |||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-001 | Jul 20, 2012 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,207,297
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 494298 | ➤ Sign Up | |||
| Austria | 496062 | ➤ Sign Up | |||
| Australia | 2005238445 | ➤ Sign Up | |||
| Australia | 2005271232 | ➤ Sign Up | |||
| Australia | 2005295183 | ➤ Sign Up | |||
| Australia | 2012203602 | ➤ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
